Finding Retinal Biomarkers in Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

93 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-10

Study Completion Date

2024-12-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CSF Alzheimer's disease (AD) biomarkers are the only one that reflect both Aβ and tau pathologies. There is increasing evidence for the presence of AD abnormalities in the retina of AD patients. Recent studies showed that they can be detected in living patients. Thus, retinal AD-linked abnormalities might be used as alternative diagnostic biomarkers for AD.

FIREBALZ study aims at identifying and validating retinal biomarkers for the diagnosis of Alzheimer's disease.

The study will include 160 patients in whom LP is indicated for assessment of CSF AD biomarkers according to French health authority (HAS) recommendations. Those patients will undergo a detailed neuro-ophtalmologic evaluation including retinal layers thickness evaluation (optical coherence tomography).

Univariate and multivariate analyses will be performed to test diagnostic properties of retinal parameters as compared to current diagnostic criteria including CSF biomarkers and logistic regression models will be used.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neuroretinal Biomarkers in Neurodegenerative Diseases

NCT02047760

Multiple Sclerosis

COMPLETED

Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease

NCT01937221

Mild Cognitive Impairment Mild to Moderate Cognitive Impairment

COMPLETED

Retinal and Cognitive Dysfunction in Type 2 Diabetes

NCT04281186

Retinal Function Cognitive Dysfunction Microperimetry

COMPLETED

Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease

NCT06924359

Alzheimer's Disease (AD)

RECRUITING

Relationship Between Alzheimer Disease and Diminution of the Three Macular Nervous Retinal Layers

NCT04794634

Optical Coherence Tomography Optical Coherence Tomography Angiography Retinal Thickening +5 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers are the only one that reflect both Aβ and tau pathologies. There is increasing evidence for the presence of AD abnormalities in the retina of AD patients. Recent studies showed that they can be detected in living patients. Thus, retinal AD-linked abnormalities might be used as alternative diagnostic biomarkers for AD.

FIREBALZ study aims at identifying and validating retinal biomarkers for the diagnosis of Alzheimer's disease.

The study will include 160 patients in whom lumbar puncture is indicated for assessment of CSF AD biomarkers according to French health authority recommendations. All patients will be recruited in the Cognitive Neurology Center (CMRR Paris Nord Ile-De-France), Paris, France. Patients will undergo a detailed neuro-ophtalmologic evaluation including complete ophthalmologic work-up to rule out chronic retinal pathology and retinal layers thickness evaluation (optical coherence tomography).

Inclusion period will be 40.5 months, Study duration for participants will be 6 at 12 weeks.

Two groups of patients will be defined for comparison according to LP results : patients with AD according to McKhann 2011 criteria and patients without AD Univariate and multivariate analyses will be performed to test diagnostic properties of retinal parameters and logistic regression models will be used.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Detailed ophthalmologic examination

* Visual acuity
* Eye pressure measurement
* Eye crystalline examination
* Fundus examination
* Optical coherence tomography of the retina
* Retinophotos

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient managed at the cognitive neurology center for cognitive impairment with a defined LP indication for the assessment of CSF AD biomarkers according to French National Health Agency recommandations in a clinical practice setting
* Patients with National Health Insurance coverage
* Patients willing to participate to the research and sign informed consent

Exclusion Criteria

* Patient refusing to participate to research or unable to sign informed consent
* Patients without indication or displaying contraindication of LP
* Chronic retinal pathology interfering with analysis :

* chronic glaucoma
* diabetic retinopathy
* severe hypertensive retinopathy
* Contraindication to brain MRI
* Other pathology considered as severe and impairing life expectancy

Eligible Sex

ALL

Accepts Healthy Volunteers

No